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Abstract
OBJECTIVE—Although prior authorization and prospective audit with feedback are both 
effective antimicrobial stewardship program (ASP) strategies, the relative impact of these 
approaches remains unclear. We compared these core ASP strategies at an academic medical 
center.
DESIGN—Quasi-experimental study.
METHODS—We compared antimicrobial use during the 24 months before and after 
implementation of an ASP strategy change. The ASP used prior authorization alone during the 
preintervention period, June 2007 through May 2009. In June 2009, many antimicrobials were 
unrestricted and prospective audit was implemented for cefepime, piperacillin/tazobactam, and 
vancomycin, marking the start of the postintervention period, July 2009 through June 2011. All 
adult inpatients who received more than or equal to 1 dose of an antimicrobial were included. The 
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primary end point was antimicrobial consumption in days of therapy per 1,000 patient-days (DOT/
1,000-PD). Secondary end points included length of stay (LOS).
RESULTS—In total, 55,336 patients were included (29,660 preintervention and 25,676 
postintervention). During the preintervention period, both total systemic antimicrobial use (−9.75 
DOT/1,000-PD per month) and broad-spectrum anti-gram-negative antimicrobial use (−4.00 DOT/
1,000-PD) declined. After the introduction of prospective audit with feedback, however, both total 
antimicrobial use (+9.65 DOT/1,000-PD per month; P < .001) and broad-spectrum anti-gram-
negative antimicrobial use (+4.80 DOT/1,000-PD per month; P < .001) increased significantly. 
Use of cefepime and piperacillin/tazobactam both significantly increased after the intervention (P 
= .03). Hospital LOS and LOS after first antimicrobial dose also significantly increased after the 
intervention (P = .016 and .004, respectively).
CONCLUSIONS—Significant increases in antimicrobial consumption and LOS were observed 
after the change in ASP strategy.
Antimicrobial stewardship programs (ASPs) are multifaceted, interdisciplinary approaches 
to optimize anti-infective therapy and address emerging resistant pathogens.1,2 Guidelines 
for stewardship identify several potential strategies, including 2 core “active” methods: 
formulary restriction with prior authorization and prospective audit with feedback to 
prescribers. Prior authorization permits use of select agents after approval from an ASP team 
member, whereas prospective audit with feedback utilizes postprescriptive reviews 
conducted by the ASP to recommend changes in agent selection, dosing, or duration of 
therapy.2,3
Published literature supports both methods as being effective strategies to decrease 
antimicrobial exposure, decrease costs, and improve clinical outcomes.4–9 However, 
because these 2 ASP methods have not been compared, the most effective approach remains 
unclear.2,10 Implementation of ASPs is increasingly common, and widespread adoption of 
stewardship interventions has been promoted by professional and governmental 
organizations.2,11,12 This study aims to compare an ASP based on prior authorization alone 
to one combining prior authorization and prospective audit with feedback.
METHODS
Setting and Patients
We examined antimicrobial use and length of stay (LOS) before and after a change in ASP 
approach at the Hospital of the University of Pennsylvania, a 776-bed tertiary care academic 
medical center in Philadelphia. Approval was obtained from the University of Pennsylvania 
Institutional Review Board. All inpatients at least 18 years of age who received at least 1 
dose of any oral or intravenous antibacterial or antifungal agent were included. To maintain 
independency of antimicrobial prescribing practices, only the first admission for each 
individual was included during the study period.
ASP
The hospital ASP was implemented in 1993, using formulary restriction with prior 
authorization.1 Prior authorization was provided by infectious diseases–trained clinical 
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pharmacists, infectious diseases fellows, and the infectious diseases consult service, as 
described previously.13 Through May 2009, antimicrobials that were broad spectrum, 
associated with resistant organisms, associated with serious adverse events, or costly were 
restricted, requiring prior authorization from the ASP team before dispensing from the 
pharmacy. This included commonly used broad-spectrum agents such as cefepime and 
piperacillin/tazobactam as well as antifungals. Vancomycin was available for 72 hours 
without prior authorization, but further use required ASP approval.
Requests for prior authorization increased over time, many for empiric broad-spectrum 
antibiotic regimens. To better utilize ASP resources, restriction categories were reassessed. 
In June 2009, the restriction was lifted for most antimicrobial agents on formulary, including 
the broad-spectrum agents cefepime, piperacillin/tazobactam, and vancomycin. For these, 
prospective audit with feedback was also introduced in June 2009. Audits occurred Monday 
through Friday by 3 infectious diseases–trained clinical pharmacists and included all patients 
in the hospital with an active order for any of those agents. Suggested modifications, if 
necessary, were communicated to the covering provider, and acceptance of the 
recommendations was at their discretion. Prior authorization, conducted in the same manner 
as before, remained for other broad-spectrum and/or costly agents (including aztreonam, 
ceftazidime, daptomycin, levofloxacin, linezolid, and meropenem) and for antifungal agents 
(Figure 1).
For this analysis, the preintervention period contained all patients admitted during the 24 
months before the ASP change, June 2007 through May 2009. The postintervention period 
included admissions during the 24 months after the change, July 2009 through June 2011. 
June 2009 was excluded from both periods, as this was a transitional time for both 
prescribers and the ASP.
Outcome Assessment
The primary outcome was antimicrobial doses administered measured by days of therapy 
(DOT), the preferred metric of antimicrobial use.14 A single DOT is recorded for each 
individual antimicrobial administered to a patient on a given day regardless of dose and 
frequency.15 A complementary measure of antimicrobial use, length of therapy (LOT), 
corresponds to each day a patient receives any systemic antimicrobial therapy, regardless of 
the number of agents or doses.16 For example, an individual who receives cefepime for 3 
days contributes 3 DOT and 3 LOT, whereas a patient receiving both cefepime and 
vancomycin for 3 days contributes 6 DOT but 3 LOT. Although the primary outcome 
quantified composite use of all 6 broad-spectrum anti-gram-negative antibiotics on 
formulary (aztreonam, cefepime, ceftazidime, levofloxacin, piperacillin/tazobactam, and 
meropenem), subanalyses focused on cefepime and piperacillin/tazobactam, the specific 
anti-gram-negative agents for which the stewardship approach changed from prior 
authorization to prospective audit.
Additional end points evaluated included total hospital LOS and LOS after receipt of first 
dose of systemic antimicrobial, both measured in days for all patients who received at least 1 
dose of an antimicrobial. Appropriateness of empiric antibiotic selection for the subset of 
patients with bloodstream infections (BSIs) caused by gram-negative organisms was also 
Mehta et al. Page 3













assessed (with the exception of the first year of the preintervention period because 
microbiology data were not available before May 2008). Empiric antibiotic regimens were 
evaluated by a blinded infectious diseases–trained clinical pharmacist on the following 
criteria: (1) the antibiotic(s) were active against the pathogen; (2) active antibiotic(s) were 
administered within 24 hours of the blood culture; (3) the antibiotic(s) used were of the 
narrowest spectrum available based on the results of susceptibility testing and the reviewers’ 
opinion; and (4) in the case of multiple antibiotic agents, redundant or overlapping spectra of 
activity were minimized.
Control Outcomes
To account for factors that could impact antimicrobial use and LOS other than the change in 
ASP strategy, we examined 3 additional antimicrobial groups.17,18 These included (1) all 
systemic antibiotics and antifungals except the 3 drugs that were prospectively audited 
(referred to as nonaudited antimicrobials), to uncover trends in total antimicrobial use during 
the study period; (2) vancomycin, the most commonly used broad-spectrum anti-gram-
positive agent at our institution; and (3) all systemic antifungal drugs, to provide a 
nonequivalent dependent variable. Nonequivalent dependent variables are outcome variables 
similar to the primary outcome and subject to the same alternative causes of an observed 
effect but are not directly affected by the intervention.
Data Source
All data were obtained from the Penn Data Store (PDS), a centralized data repository of 
information from all electronic clinical systems across the Penn Medicine Health System. 
PDS contains demographics, diagnoses, procedures, laboratory results, medication orders, 
and doses administered for all inpatient and outpatient visits. For this study, demographic, 
microbiology, medication orders, and administration records were extracted for inpatients 
admitted during the 4-year study period.
Statistical Analysis
Patient characteristics were compared between the 2 time periods using the χ2 or Fisher 
exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. 
Antimicrobial consumption was evaluated on a monthly basis. All included patients were 
assigned a month (1–49) according to admission date. DOT, LOT, and LOS for each patient 
were calculated, totaled for each month, and then standardized to 1,000 patient-days (DOT/
1,000-PD, LOT/1,000-PD, and days/1,000-PD, respectively), using total patient-days for all 
admissions in that month irrespective of antimicrobial administration.15
Because antimicrobial consumption for a given month is likely related to that in previous 
months, we used interrupted time series analysis.17,19 The generalized autoregressive 
conditional heteroskedasticity (GARCH) model was fitted for all DOT and LOS measures. 
GARCH allows for the assessment of autocorrelation, volatility, and the influence of an 
exogenous input, such as the change in ASP method.20,21
For the treatment of gram-negative BSIs, the frequency of adequate empiric therapy, 
redundant spectra of activity, and excessively broad therapy were compared in the 
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preintervention and postintervention groups using the χ2 test. All analyses were performed 
with STATA statistical software (ver. 12.1; StataCorp, College Station, TX).
RESULTS
Patient Characteristics
We identified 55,336 patients who received antimicrobial therapy from June 2007 through 
June 2011: 29,660 patients before the intervention and 25,676 after the intervention. Patients 
in both groups were similar with regard to baseline demographics collected at admission 
(Table 1).
Consumption of Broad-Spectrum Anti-Gram-Negative Agents
During the preintervention period, use of broad-spectrum anti-gram-negative antibiotics was 
declining at a rate of −4.00 DOT/1,000-PD per month. However, during the postintervention 
period, use increased by 0.80 DOT/1,000-PD per month, indicating that the change in ASP 
was associated with a slope change of 4.80 DOT/1,000-PD per month (P < .001; Table 2, 
Figure 2), or an increase of 0.49% per month after the intervention. Similarly, after 
decreasing during the 2 years before the ASP change, use of cefepime and piperacillin/
tazobactam significantly increased following the transition to prospective audit with 
feedback by 3.21 DOT/1,000-PD per month (P = .003; Table 2, Figure 2). This represented 
a 1.1% increase in use per month through the postintervention period. The use of the other 4 
broad-spectrum anti-gram-negative antibiotics, for which prior authorization was required in 
both time periods, decreased before the intervention, with no significant increase after the 
intervention (slope change, 1.62 DOT/1,000-PD per month; P = .100; Table 2, Figure 2).
Consumption of Other Antimicrobial Agents
Overall use of all systemic antimicrobial agents significantly increased after the change in 
ASP method (P < .001; Table 2, Figure 3). Vancomycin use declined before the intervention 
but significantly increased after the intervention (P = .005; Table 2, Figure 3). While use of 
nonaudited antimicrobials also significantly increased after the change in ASP methods (P 
< .001), the slope during the postintervention period continued to decline at −1.87 DOT/
1,000-PD per month (Table 2, Figure 3). The LOT of all systemic antimicrobials declined 
before the intervention by −2.30 LOT/1,000-PD per month, and, despite a significant 
increase in slope (P = .029), use continued to decrease after the intervention by −0.33 LOT/
1,000-PD per month.
Antifungal agents, the nonequivalent dependent control variable, followed similar patterns 
of use as the primary variable. Before the intervention, use of these drugs decreased by 
−1.77 DOT/1,000-PD per month. After the intervention, use increased by 0.65 DOT/1,000-
PD per month, representing a slope change of 2.42 DOT/1,000-PD per month (P = .001; 
Table 2, Figure 3).
LOS
Before the intervention, total hospital LOS for patients receiving antimicrobials was 
decreasing at a rate of −1.57 days/1,000-PD per month; however, LOS following the ASP 
Mehta et al. Page 5













transition increased by 1.94 days/1,000-PD (P = .016). When limiting the analyses to LOS 
after the first dose of a systemic antimicrobial, we found a similar reversal of trends (−1.42 
days/1,000-PD per month before the intervention; +2.30 days/1,000-PD after the 
intervention; P = .004; Figure 4).
Empiric Antibiotic Selection
A total of 488 patients with gram-negative BSIs were identified from the available 
microbiology data. There were 165 BSI episodes available in 13 months of the 
preintervention period and 311 in 24 months of the postintervention period. There was no 
significant difference in the proportion of inappropriate empiric antibiotic regimen selection 
between the 2 groups (18.2% vs 18.0%; P = .962). Similarly, there were no significant 
differences in the proportion of redundant antibiotic regimen (11.5% vs 10.3%; P = .681) 
and in excessively broad antibiotic coverage (42.4% vs 37.3%; P = .275) before and after 
the intervention.
DISCUSSION
The results of this study represent a formal comparison of the 2 core antimicrobial 
stewardship methods within a single institution. Our findings suggest that the change from 
prior authorization to prospective audit with feedback was associated with a significant 
increase both in use of the affected antimicrobials and in overall use of all antimicrobial 
agents. Furthermore, broad-spectrum anti-gram-negative agents that still required prior 
authorization during both time periods continued to decline in use after the change in ASP. 
Last, the overall change in stewardship approach was associated with a significant increase 
in hospital LOS.
Prior studies of stewardship interventions have found implementation of either prior 
authorization or prospective audit with feedback to be effective strategies for decreasing 
antimicrobial exposure, decreasing costs, and improving clinical outcomes.4–6,8,9 Elligsen et 
al7 performed a quasi-experimental study to assess the effects of the implementation of 
prospective audit with feedback in the intensive care units at a tertiary medical center using 
adequate design and statistical approaches. The ASP was associated with an immediate and 
sustained decrease in targeted antibiotic consumption as well as in overall antibiotic use. 
However, this study, like prior stewardship studies, compared drug use in the presence of an 
ASP to drug use in its absence. One multicentered study, conducted by Cosgrove et al,22 
provided the first insight into a possible benefit of an ASP utilizing both active strategies. 
The intervention, a postprescriptive review overlaid on any ASP already established at the 
study site, was implemented at 5 tertiary care academic medical centers. Although their 
findings were heterogeneous, the sites with prior authorization-based ASPs had significant 
reductions in antimicrobial consumption after the postprescriptive review was implemented, 
whereas sites without an ASP had significant increases in antimicrobial use after the 
intervention. These results suggest that an ASP combining both active strategies may be 
most effective.
LOS as a clinical outcome is a potentially important measure of ASP effectiveness.3 
Additionally, LOS is an important factor in healthcare cost analysis.23 The benefit of ASP 
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efforts in improving LOS has been varied in published studies. Several studies could not 
establish a significant impact on LOS.4,5,7 However, Gentry et al24 found a significant 
reduction in LOS after a change in the ASP program at a Veterans Affairs medical center. 
Previously, ASP at their hospital relied on prior authorization from an infectious diseases 
physician for use of restricted or nonformulary antimicrobials beyond 24 hours. Their ASP 
was changed with the inclusion of an infectious diseases clinical pharmacist who 
prospectively audited the use of the drugs. While this analysis appears similar to our study, it 
is important to note that their comparison is between physician- and pharmacist-staffed 
ASPs. As was demonstrated in another study, these 2 groups differ in stewardship 
effectiveness.13 Our study, however, is a comparison of the 2 active ASP methods used by 
the same ASP personnel in the same setting. LOS appears to have significantly increased 
after the change in ASP; however, the mechanism for this finding is unknown.
There are several potential limitations to our study. First, process measures, such as 
antimicrobial use, are considered inadequate when used alone to evaluate ASP interventions 
because such outcomes do not demonstrate a direct clinical benefit.12 Standardized and 
validated clinical end points have not been established in retrospective studies of anti-
infective therapy, a substantial knowledge gap in stewardship research.11 Drug utilization 
was a relatively easy metric to capture in this first comparison of ASP methods. 
Additionally, a panel of experts recently recommended DOT as one of 5 quality metrics for 
ASP evaluation as well as identifying it as a metric for public reporting.14 However, DOT 
assesses only antimicrobial doses that were administered to the patient. We were unable to 
quantify the effect of each ASP method on preventing erroneous or unnecessary therapy.
Another important limitation is that the influence of factors other than the change in ASP 
cannot be fully excluded. Throughout the 4 years of this study, changes in patient 
demographics, bacterial resistance rates, or hospital characteristics could have impacted 
antimicrobial use patterns. Other, more difficult to measure factors could also impact drug 
use, such as prescribing philosophies or attitudes of the ASP team after liberalization of 
many antimicrobials. Control variables were used to assess this, in particular, antifungal 
agents. The increased use of antifungals after the intervention suggests that external factors 
may have lead to a global trend for increased use of all antimicrobials. However, 
consumption of the 4 broad-spectrum anti-gram-negative antibiotics that required prior 
authorization during both time periods continued to decline after the intervention, in contrast 
to cefepime and piperacillin/tazobactam. Additionally, the use of nonaudited antimicrobials 
also exhibited a positive change in slope, although the overall trend showed a continued 
decline in use during the postintervention period. Together, these findings suggest 2 
possibilities: (1) antifungals were not an adequate nonequivalent dependent control due 
factors specific to these drugs or (2) the postintervention increase in use of unrestricted 
broad-spectrum drugs occurred independently from the increase in antifungal use. The 
presence of such factors must also be taken into account when interpreting the LOS findings 
as a possible alternative explanation for the increased stay.
This study observed a significant increase in antimicrobial use after the inclusion of 
prospective audit with feedback intervention to an ASP based on prior authorization. While 
other explanations may limit the interpretation of these findings, our results suggest a 
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difference may be present between the 2 core ASP strategies. Further comparative studies 
focused on treatment-related clinical outcomes and microbiologic sequelae would strengthen 
the case for one particular antimicrobial stewardship method over others.
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Timeline of antimicrobial stewardship program (ASP) strategies for broad-spectrum 
antimicrobials at the Hospital of the University of Pennsylvania.
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Trends in consumption of broad-spectrum anti-gram-negative agents (days of therapy per 
1,000 patient-days) by month for the 4-year study period.
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Trends in consumption for all systemic antimicrobials, nonaudited antimicrobials, 
vancomycin, and antifungal agents (days of therapy per 1,000 patient-days) by month for the 
4-year study period.
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Trends in length of stay for total hospitalization and in length of stay after receipt of 
antimicrobials by month for the 4-year study period.
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Age, median (IQR), years 54 (38–67) 54 (38–67)
Female sex 15,866 (53.5) 13,564 (52.8)
White race 16,700 (56.3) 15,053 (58.6)
β-lactam allergy 2,868 (9.7) 2,675 (10.4)
Admitting service
  Medical 9,340 (31.5) 7,692 (30.0)
  Surgical 16,420 (55.4) 14,741 (57.4)
  Other 3,900 (13.1) 3,243 (12.6)
Admission source
  Routine 14,960 (50.4) 12,781 (49.8)
  Emergency department 8,459 (28.5) 7,075 (27.6)
  Transfer from outside facility 3,624 (12.2) 3,713 (14.5)
  Other 2,617 (8.8) 2,107 (8.1)
Risk mortality score
  1: Minor risk of mortality 16,353 (55.3) 12,825 (50.4)
  2: Moderate risk of mortality 6,285 (21.2) 5,579 (21.9)
  3: Major risk of mortality 4,053 (13.7) 4,048 (15.9)
  4: Extreme risk of mortality 2,890 (9.8) 3,006 (11.8)
Severity of illness score
  1: Minor severity of illness 8,988 (30.4) 6,371 (25.0)
  2: Moderate severity of illness 9,867 (33.3) 8,418 (33.1)
  3: Major severity of illness 6,770 (22.9) 6,681 (26.2)
  4: Extreme severity of illness 3,956 (13.4) 3,988 (15.7)
NOTE. Data are no. (%), unless otherwise indicated. Risk mortality and severity of illness scores are calculated on admission according to All 
Patient Refined Diagnosis-Related Group. IQR, interquartile range.
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TABLE 2
Antimicrobial Consumption over Time
Slope, DOT/1,000-PD per month (95% CI)
Antimicrobial group Preintervention Postintervention Changea P
Broad-spectrum anti-gram-negative agents
All agents −4.00 (−6.11, −1.90) 0.80 (−0.23, 1.83) 4.80 (2.46, 7.14) <.001
Cefepime and piperacillin/tazobactam −1.86 (−3.87, 0.14) 1.35 (0.79, 1.91) 3.21 (1.13, 5.30) .003
Aztreonam, ceftazidime, levofloxacin, and meropenem −2.15 (−4.04, −0.25) −0.53 (−0.88, −0.17) 1.62 (−0.31, 3.55) .100
Other antimicrobial agents
All systemic antimicrobials −9.75 (−13.69, −5.82) −0.10 (−1.77, 1.57) 9.65 (5.38, 13.93) <.001
Vancomycin −0.46 (−0.86, −0.01) 0.43 (−0.04, 0.89) 0.89 (0.27, 1.50) .005
Antifungals −1.77 (−3.07, −0.47) 0.65 (0.21, 1.09) 2.42 (1.05, 3.79) .001
Nonaudited antimicrobials −7.43 (−9.98, −4.89) −1.87 (−3.18, −0.57) 5.56 (2.70, 8.42) <.001
NOTE. CI, confidence interval; DOT/1,000-PD, days of therapy per 1,000 patient-days.
a
Difference between the preintervention and postintervention slopes.
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